Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.59 |
| ▸ | CLPP | Q16740 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133574 | 1.00 | GRM5 (0.59) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3141641 | 0.95 | GRM5 (0.56) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3141649 | 0.95 | GRM5 (0.56) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3141564 | 0.92 | GRM5 (0.51) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3141572 | 0.92 | GRM5 (0.51) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3137969 | 0.86 | GRM5 (0.55) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3137973 | 0.86 | GRM5 (0.55) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3136385 | 0.84 | GRM5 (0.57) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3136391 | 0.84 | GRM5 (0.57) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL3137633 | 0.83 | CNR1 (0.46) | GRM5CLPPMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364222-B2 | Cyclic amine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2019-07-30 | — | — | US | disclosed |
| US-20180370916-A1 | CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2018-12-27 | — | — | US | disclosed |
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-1896464-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006129199-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM1, GRIK5 | GRM5 1/4885CLPP 4732/4885ATM 4195/4885 |
| US-20180370916-A1 | CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF | RORC, RORB, HRH3 | GRM5 285/4885CLPP 4876/4885ATM 3151/4885 |
| US-10364222-B2 | Cyclic amine derivative and medical use thereof | RORC, RORB, HRH3 | GRM5 285/4885CLPP 4876/4885ATM 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.